Servier

Servier expands global footprint post Shire deal

https://pharmaphorum.com/news/servier-expands-footprint-shire/

Shire’s $2.4bn oncology sell-off seen as Takeda spoiler

https://pharmaphorum.com/news/shire-sell-cancer-business-servier-2-4bn/

Safety restrictions spell the end for Servier osteoporosis drug

https://pharmaphorum.com/news/servier-end-production-osteoporosis-drug/

Servier and Pfizer begin trials for off-the-shelf T-cell cancer therapy

https://pharmaphorum.com/news/servier-and-pfizer-car-t/

After taking lead in CAR-T, Cellectis drug snapped up by Pfizer and Servier

https://pharmaphorum.com/news/after-taking-lead-in-car-t-cellectis-drug-snapped-up-by-pfizer-and-servier/

Close in 10 seconds

Pharmaphorum.com

Search